Image

Debulking Atherectomy Versus Stent Angioplasty for Limb Ischaemia of Diabetic Lower Limb Atherosclerosis-occlusive Disease.

Debulking Atherectomy Versus Stent Angioplasty for Limb Ischaemia of Diabetic Lower Limb Atherosclerosis-occlusive Disease.

Recruiting
40-80 years
All
Phase N/A

Powered by AI

Overview

In order to assessment the safety and efficacy of debulking atherectomy versus stent angioplasty for limb ischaemia of diabetic lower limb atherosclerosis-occlusive disease, we intend to conduct a prospective, multicenter, randomized controlled, non-inferiority trial. The main surgical methods included stent angioplasty group (Nickel-titanium self-expanding bare stent) and debulking atherectomy group (Excimer laser atherectomy combined with drug-coated balloon angioplasty). The sample size was 244 patients, and the patients were followed up at 30 days, 180 days, and 365 days after operation.

Eligibility

Inclusion Criteria:

  1. Age 40-80 years old
  2. Rutherford grade 2 to 5
  3. Patients clinically diagnosed with arteriosclerosis obliterans of lower extremity (stenosis of lower extremity arteries greater than 70% or occlusion) and complicated with diabetes
  4. The target vessel diameter ≥4mm
  5. The total target length of the lesion is 30-210mm
  6. The subject is able and willing to comply with all requirements, including 12-month follow-up and evaluation, voluntary participation and informed consen
  7. Patients with ipsilateral iliac artery inflow tract patency (stenosis ≤50%) or ipsilateral iliac artery inflow tract lesions and successful management (residual stenosis < 30% after treatment, no severe (≥ grade D) flow-limiting dissection , no thrombosis, embolism or other serious adverse events)
  8. Patients with at least one infrapopliteal artery for patency of the affected lateral foot before or after intraoperative treatment (stenosis ≤50%)

Exclusion Criteria:

  1. Patients with vasculitis or Berger disease
  2. Patients with contraindications to antiplatelet, anticoagulant and thrombolytic drugs
  3. Patients who are allergic to contrast agents and nickel titanium materials
  4. Patients with severe coagulation dysfunction or severe infection that is not under control and should not undergo surgery
  5. Severe renal dysfunction (creatinine > 221umol/L)
  6. Patients who received local or systemic thrombolytic therapy within 48 hours before surgery
  7. Patients who had acute myocardial infarction within 30 days before surgery
  8. Patients who had undergone major surgical procedures (heart, abdominal, or peripheral vascular open surgery) within 30 days before surgery
  9. Patients who had a stroke within 6 months before surgery
  10. Patients whose target arteries had received endovascular surgery within 14 days prior to surgery and patients who had other elective surgery plans during the study period
  11. Patients with end-stage renal disease
  12. Patients with previous major amputation of the target limb or restenosis after stent or bypass surgery for the target lesion
  13. Patients with perforation, dissection, or other vascular injury requiring stenting or surgical operation in the approach or target vessel prior to enrollment
  14. Patients with a life expectancy of < 12 months
  15. A woman who is pregnant or breastfeeding
  16. Patients who are participating in clinical trials of other drugs or devices that do not meet trial endpoints
  17. Patients considered unsuitable for this trial by the investigators Exclusion criteria for angiography
  18. Patients with severe calcification of the target lesions
  19. Patients with aneurysms in the target vessels
  20. Patients with acute or subacute thrombus in the target vessel
  21. Patients with artificial vessels placed in the limb on the same side of the target vessel

Study details
    Peripheral Arterial Disease

NCT05670171

Xuanwu Hospital, Beijing

28 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.